Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fructose SCHEMBL8469522 | 1.00 | CYP2C9 (0.54) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL80090 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL9711052 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL7549336 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL19744235 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL159418 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL16196803 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL1054095 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL7707744 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL7524214 | 0.98 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190083452-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | LOTHERA, LLC | 2019-03-21 | — | — | US | claimed |
| EP-2429586-A1 | ORALLY DISINTEGRATING EXCIPIENT | Jrs Pharma GmbH+Co.kG (DE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132431-A1 | ORALLY DISINTEGRATING EXCIPIENT | JRS PHARMA GMBH+CO.KG (DE) | 2010-11-18 | — | — | WO | disclosed |
| EP-0973507-A4 | DOSAGE FORM EXHIBITING RAPID DISPERSE PROPERTIES, METHODS OF USE AND PROCESS FOR THE MANUFACTURE OF SAME | THERICS INC (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1139773-A4 | CONTROLLING RELEASE OF ACTIVE AGENTS FROM A CHEWING GUM COATING | WRIGLEY W M JUN CO (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1139773-A1 | CONTROLLING RELEASE OF ACTIVE AGENTS FROM A CHEWING GUM COATING | WM. WRIGLEY JR. COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035295-A1 | CONTROLLING RELEASE OF ACTIVE AGENTS FROM A CHEWING GUM COATING | WM. WRIGLEY JR. COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0973507-A1 | DOSAGE FORM EXHIBITING RAPID DISPERSE PROPERTIES, METHODS OF USE AND PROCESS FOR THE MANUFACTURE OF SAME | Therics, Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998036738-A1 | DOSAGE FORM EXHIBITING RAPID DISPERSE PROPERTIES, METHODS OF USE AND PROCESS FOR THE MANUFACTURE OF SAME | THERICS, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
| US-5380541-A | Sucralose compositions | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1995-01-10 | — | — | US | disclosed |
| WO-1989003182-A1 | SUCRALOSE COMPOSITIONS | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1989-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083452-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | NCSTN, CHLSN, CNTN1 | CYP2C9 2686/4885TSHR 4864/4885PDE4A 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.